414.68

1.86% 7.59

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Financials Why MDGL Down? Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is traded at $414.68, with a volume of 465.90K. It is up +1.86% in the last 24 hours and up +32.32% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Previous Close:

$407.09

Open:

$405.29

24h Volume:

465.90K

Relative Volume:

1.30

Market Cap:

$9.21B

Revenue:

Net Income/Loss:

$-518.67M

P/E Ratio:

-16.51

EPS:

-25.12

Net Cash Flow:

$-438.32M

1W Performance:

+12.12%

1M Performance:

+32.32%

6M Performance:

+23.33%

1Y Performance:

+66.75%

1-Day Range:

$404.16

$419.99

1-Week Range:

$351.31

$419.99

52-Week Range:

$200.63

$419.99

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

404-380-9263

Address

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Employee

528

Twitter

@MadrigalPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

MDGL's Discussions on Twitter

Compare MDGL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDGL Madrigal Pharmaceuticals Inc	414.68	8.72B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy
Feb-27-25	Reiterated	H.C. Wainwright	Buy
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform
Apr-22-24	Initiated	BofA Securities	Underperform
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral
Mar-06-24	Initiated	Citigroup	Buy
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

Aug 20, 2025

Rezdiffra's EU Approval: A Strategic Inflection Point for Madrigal and the MASH Market - AInvest

Aug 20, 2025

Madrigal Regains Lead With Rezdiffra MASH Approval In EU - insights.citeline.com

Aug 20, 2025

Madrigal Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftWeekly Trade Analysis & Expert Curated Trade Setup Alerts - newsyoung.net

Aug 20, 2025

Madrigal’s MASH treatment Rezdiffra receives EU approval By Investing.com - Investing.com Nigeria

Aug 19, 2025

Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN

Aug 19, 2025

Madrigal’s MASH treatment Rezdiffra receives EU approval - Investing.com

Aug 19, 2025

Madrigal Pharmaceuticals' Rezdiffra Becomes First Approved Treatment for MASH in the European Union - Quiver Quantitative

Aug 19, 2025

Madrigal Receives European Commission Approval for - GlobeNewswire

Aug 19, 2025

Madrigal Pharmaceuticals, Inc. Receives European Commission Approval for Rezdiffra for the Treatment of MASH with Moderate to Advanced Liver Fibrosis - MarketScreener

Aug 19, 2025

Aug 18, 2025

Insider Selling at Madrigal Pharmaceuticals: Signal or Noise in the NASH Therapeutics Sector? - AInvest

Aug 18, 2025

Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock By Investing.com - Investing.com Nigeria

Aug 18, 2025

Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock - Investing.com

Aug 18, 2025

Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD - Investing.com

Aug 18, 2025

Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD By Investing.com - Investing.com UK

Aug 18, 2025

Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs amid Wegovy approval - Investing.com Canada

Aug 18, 2025

Madrigal Pharmaceuticals Faces Market Jitters Amid New Rival - TipRanks

Aug 18, 2025

Why Nova Nordisk (NVO) Stock Is Climbing Today - Yahoo Finance

Aug 18, 2025

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH - Investing.com Canada

Aug 18, 2025

Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN

Aug 18, 2025

Aug 17, 2025